This guideline was developed by a multidisciplinary working group convened by the National Breast Cancer Centre**.
|Associate Professor Martin Stockler||Medical Oncologist (Chair)|
|Dr Fran Boyle||Medical Oncologist|
|Dr Nicholas Wilcken||Medical Oncologist|
|Professor Ian Olver||Medical Oncologist|
|Mr David Oliver||Surgeon|
|Dr Melissa Bochner||Surgeon|
|Dr Liz Kenny||Radiation Oncologist|
|Ms Lee Millard||Breast Care Nurse|
|Dr Julie Thompson||General Practitioner|
|Ms Susan Timbs||Consumer Representative|
Dr Elmer Villanueva, Ms Rosemary Vagg, Dr Alison Evans, Mr Andy Moore, Dr Karen Luxford, Dr Helen Zorbas
Full details of trial results are provided in the document Aromatose Inhibitors as Adjuvant Therapy for Post-Menopausal Women with Hormone Receptor-Positive Early Breast Cancer: Evidence Summary which can be accessed via the NBCC** website at www.nbcc.org.au
** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
As of July 2006. For updates after this date go to http://www.health.gov.au/pbs/
|Tamoxifen:||Treatment of hormone-dependent breast cancer.|
|Anastrozole:||Treatment of hormone-dependent breast cancer in post-menopausal women. Not subsidised for primary prevention of breast cancer.|
|Letrozole:||Treatment of hormone-dependent advanced breast cancer in post-menopausal women. Not subsidised for primary prevention of breast cancer.|
|Exemestane:||Treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate. Not subsidised for primary prevention of breast cancer.|
Priority topic areas for NBOCC guideline development are determined in consultation with key stakeholders including experts in relevant disciplines and consumer representatives. A specific multidisciplinary Working Group, including consumers, is established for each topic identified and is involved in all aspects of guideline development. A systematic evidence review is undertaken for each guideline. All members are asked to declare any conflicts of interest and these declarations are recorded. The content of the guideline is not influenced by any external funding body. The guideline is reviewed externally by key stakeholders and the wider community and endorsement is sought from relevant professional colleges and groups in Australia.
Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer was prepared and produced by:
National Breast and Ovarian Cancer Centre
Level 1, Suite 103, 355 Crown Street Surry Hills NSW 2010
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 Frecall 1800 624 973
National Breast Cancer Centre 2006
ISBN Print: 978-1-74127-010-5 Online: 978-174127-011-2 CIP: 616.99449061
This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the National Breast Cancer Centre. Requests and enquiries concerning reproduction and rights should be addressed to the Corporate Communications Manager, National Breast and Ovarian Cancer Centre.
National Breast Cancer Centre. Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer. National Breast Cancer Centre, Camperdown, NSW, 1450.
National Breast and Ovarian Cancer Centre does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. National Breast and Ovarian Cancer Centre develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.
National Breast and Ovarian Cancer Centre is funded by the Australian Government Department of Health and Ageing.